Beneficial effect of ivabradine against cardiovascular diseases
Maria Alessandra Gammone1, Graziano Riccioni2, Francesco Massari3
1Clinical Nutrition Unit, Department of Oral Medical and Biotechnological Sciences, Via dei Vestini 31, University of Chieti-Pescara, Italy, m.alessandra.gammone@gmail.com.
Insights
Ivabradine (IVA) effectively lowers heart rate, offering benefits for patients with coronary artery disease (CAD) and heart failure (HF). This medication demonstrates comparable efficacy to other anti-anginal agents with a good safety profile.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Coronary artery disease (CAD) and heart failure (HF) are leading global health concerns.
- Elevated heart rate is independently associated with cardiovascular risk factors like atherosclerosis and ventricular dysfunction.
- Existing treatments for CAD and HF have improved mortality rates.
Purpose of the Study:
- To review recent findings on Ivabradine (IVA), a selective If current inhibitor.
- To discuss the role of heart rate reduction in managing CAD and chronic heart failure.
- To explore potential future applications of Ivabradine.
Main Methods:
- Review of recent clinical results and pharmacological data for Ivabradine.
- Analysis of Ivabradine's pharmacodynamic and pharmacokinetic properties.
- Comparison of Ivabradine's efficacy and safety with established anti-anginal agents.
Main Results:
- Ivabradine is a pure heart rate-lowering agent with proven anti-anginal and anti-ischemic effects.
- Heart rate reduction achieved with Ivabradine is beneficial in patients with CAD and chronic HF.
- Ivabradine exhibits an acceptable tolerance and safety profile.
Conclusions:
- Ivabradine is a valuable therapeutic option for managing patients with CAD and chronic HF.
- Its unique mechanism of selectively inhibiting the If current offers a distinct advantage.
- Further research may uncover additional therapeutic applications for Ivabradine.
Abstract:
Coronary artery disease (CAD) and heart failure (HF) are major worldwide threat to health and well-being. Important progress in the treatment of CAD and HF have contributed to a decline in mortality around the world. A considerable number of epidemiological studies reported a strong independent association between elevated heart rate and major cardiovascular risk factors including atherosclerosis, ventricular arrhythmias, and left ventricular dysfunction. Ivabradine (IVA) is a pure heart rate-lowering agent with well-documented anti-anginal and anti-ischemic properties comparable to well-established anti-anginal agents, such as beta-blockers and calcium channel blockers. The heart rate reduction with IVA is beneficial in patients with CAD, chronic stable angina pectoris, and chronic HF, with an acceptable tolerance and safety profile. The pharmacodynamic and pharmacokinetic properties of this drug make it an important agent in the management of patients with CAD and HF. The aim of this short review is to explore recent results with IVA, a new medication that lowers heart rate by selectively inhibiting the If current, and to describe others future potential applications.
Related Concept Videos
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
01:22Heart Failure Drugs: β-Blockers
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers